Quetiapine in the management of psychosis secondary to Huntington's disease: A case report [3]

Canadian Journal of Psychiatry

Volumn 49, Issue 6, 2004, Pages 413-

  Seitz, Dallas P ^a   Millson, Richard C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; CASE REPORT; DRUG DOSE REGIMEN; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUNTINGTON CHOREA; LETTER; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PSYCHOSIS; RATING SCALE; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 3042733763     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900617     Document Type: Letter

References (9)

1. Leroi I, Michalon M. Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. Can J Psychiatry 1998;43:933-40.
2. Naarding P, Kremer HPH, Zitman FG. Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Eur Psychiatry 2001;16:439-45.
3. Shiwach R. Psychopathology in Huntington's disease patients. Acta Psychiatr Scand 1994;90:241-6.
4. Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology 1991;41:156.
5. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Ger Psychiatry 1998;6:347-9.
6. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002;105:441-4.
7. Bonelli RM, Mahnert FA, Niederweiser G. Olanzapin for Huntington's disease: an open label study. Clin Neuropharmacol 2002;25:263-5.
8. Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol 2002;249:1114-5.
9. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal rating scale. Can J Neurol Sci 1980;7:233.